These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38429002)

  • 1. Hematologic complications after kidney and pancreas transplant in a patient with chronic myeloid leukemia.
    Yohannan B; Omo-Ogboi A; Kachira JJ; Juneja H
    Cleve Clin J Med; 2024 Mar; 91(3):183-190. PubMed ID: 38429002
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Efficacy and Safety of Flumatinib in the Treatment of Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase].
    Li Q; Jing L; Wu PQ; Han LY; Xing HY; Huang CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Román J; Martín C; Torres A; García A; Andrés P; García MJ; Baiget M
    Leuk Lymphoma; 1998 Feb; 28(5-6):541-50. PubMed ID: 9613984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrophotometric detection of RT-PCR-amplified BCR/ABL fusion transcripts. A survey performed on archival hematologic slides.
    Attadia V; Alosi M; Improta S; Zagonel V; Martinazzo G; Carbone A; Pinto A
    Am J Clin Pathol; 1997 Oct; 108(4):383-90. PubMed ID: 9322590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
    Miyamura K; Tahara T; Tanimoto M; Morishita Y; Kawashima K; Morishima Y; Saito H; Tsuzuki S; Takeyama K; Kodera Y
    Blood; 1993 Feb; 81(4):1089-93. PubMed ID: 8427990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
    Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
    Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Alyea EP; Soiffer RJ; Roy DC; Ritz J
    Blood; 1994 Oct; 84(7):2109-14. PubMed ID: 7919323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders?
    Roumier C; Daudignon A; Soenen V; Dupriez B; Wetterwald M; Lai JL; Cosson A; Fenaux P; Preudhomme C
    Haematologica; 1999 Dec; 84(12):1075-80. PubMed ID: 10586207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
    Kaeda J; O'Shea D; Szydlo RM; Olavarria E; Dazzi F; Marin D; Saunders S; Khorashad JS; Cross NC; Goldman JM; Apperley JF
    Blood; 2006 May; 107(10):4171-6. PubMed ID: 16449534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
    Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
    Ann Hematol; 2000 Aug; 79(8):424-31. PubMed ID: 10985361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of acute promyelocytic leukemia with isochromosome 17q after BCR/ABL positive chronic myeloid leukemia.
    Oren H; Düzovali O; Yüksel E; Sakizli M; Irken G
    Cancer Genet Cytogenet; 1999 Mar; 109(2):141-3. PubMed ID: 10087949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
    Corsetti MT; Lerma E; Dejana A; Cavaliere M; Figari O; Vassallo F; Abate M; Luchetti S; Piaggio G; Parodi C; Li Pira G; Manca F; Carella AM
    Exp Hematol; 2000 Jan; 28(1):104-11. PubMed ID: 10658682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.